

FY06 Peer Reviewed Medical Research Program (PRMRP)

The United States Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP) invites applications for funding for Peer Reviewed Medical Research Program (PRMRP). The Defense Appropriations Act of 2006 (Public Law 109-359) provides \$50 to fund peer-reviewed medical research. Based on congressional guidance published in previous fiscal years Defense Appropriation Acts, the PRMRP was established to provide support for military health-related research of clear scientific merit. The FY06 PRMRP Supplement is self-contained and supersedes the USAMRMC current Broad Agency Announcement.

Five different funding mechanisms that provide support for military health-related research are available. Those mechanisms include: Investigator-Initiated Award, New Program Project Award, Existing Program Project Award, Advanced Technology: Product/Technology Down-Selection or Optimization Award, and Advanced Technology: Clinical Testing/Trials (Human Subjects) Award.

Proposals must address one of the following topic areas: Advanced Proteomics, Alcoholism Research, Autism, Autoimmune Diseases (such as Scleroderma and Sjogren's Syndrome), Blood-Related Cancer Research (such as Leukemia, Lymphoma, and Multiple Myeloma), Childhood Asthma, Chronic Pain and Fatigue Research, Childhood Cancer Research, Diabetes Research, Duchenne's Disease Research, Eye and Vision Research, Fibromyalgia, Interstitial Cystitis Syndrome, Kidney Cancer Research, Lupus Research, Osteoporosis and Bone-Related Diseases, Polycystic Kidney Disease, Pulmonary Hypertension, Paget's Disease, Post traumatic Stress Disorders, Social Work Research, and Military Relevant Disease Management [with special emphasis on Antibiotic Resistance; Neurotoxicity of Mefloquine; Rehabilitation (Face and/or Eye Injury); Respiratory Infection Including Associated Respiratory Disease; Drug Abuse; Efficacy and Subsequent Clinical Guidelines for the Use of Probenecid or Other Drugs to Decrease Dosage Requirements of Oseltamivir Phosphate for the Treatment of Influenza; Human Performance Optimization; Radio-Protectants; and Mental Health Resiliency].

The PRMRP expects to fund 33 Investigator –Initiated Research Awards at \$625,000 direct costs, 2 New Program Project Awards at \$1.25M direct costs, 2 Existing program Project Awards at \$1,25M, 3 Advanced Technology: Product/Technology Down Selection or Optimization at \$940,000 direct costs, 2 Advanced Technology: Clinical Testing/Trials at \$2.5M direct costs. All mechanism can request applicable indirect costs in addition to direct cost amounts.

Please see FY06 PRMRP Supplement for complete details for submission under this Announcement. Please note that this supplement is self-contained; all information and forms needed for successful proposal submission are included within this document.

Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system. No paper copy submissions will be accepted. The CDMRP uses a two –tier review process for proposals: Scientific peer review, followed by programmatic review. Details of both tiers of review can be found in the Full Text of the Announcement.

Timelines for the FY06 PRMRP proposals are as follows: Letter of Intent are expected by April 10, 2006, Full Proposal Submission Deadline: May 9, 2006, 5:00 p.m. Eastern Time; Peer Review: July 2006, Programmatic review: September 2006; Award start date: Between October 2006 and September 2007.

For additional information or questions, please contact Pamela Fisher, Contracting/Grants Officer, U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, phone 301-619-2805, Fax (301) 619-4084, e-mail: Pam.Fisher@det.amedd.army.mil.